Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 22;8(1):294.
doi: 10.1186/1556-276X-8-294.

Synthesis of CdTe quantum dot-conjugated CC49 and their application for in vitro imaging of gastric adenocarcinoma cells

Affiliations

Synthesis of CdTe quantum dot-conjugated CC49 and their application for in vitro imaging of gastric adenocarcinoma cells

Yun-Peng Zhang et al. Nanoscale Res Lett. .

Abstract

The purpose of this experiment was to investigate the visible imaging of gastric adenocarcinoma cells in vitro by targeting tumor-associated glycoprotein 72 (TAG-72) with near-infrared quantum dots (QDs). QDs with an emission wavelength of about 550 to 780 nm were conjugated to CC49 monoclonal antibodies against TAG-72, resulting in a probe named as CC49-QDs. A gastric adenocarcinoma cell line (MGC80-3) expressing high levels of TAG-72 was cultured for fluorescence imaging, and a gastric epithelial cell line (GES-1) was used for the negative control group. Transmission electron microscopy indicated that the average diameter of CC49-QDs was 0.2 nm higher compared with that of the primary QDs. Also, fluorescence spectrum analysis indicated that the CC49-QDs did not have different optical properties compared to the primary QDs. Immunohistochemical examination and in vitro fluorescence imaging of the tumors showed that the CC49-QDs probe could bind TAG-72 expressed on MGC80-3 cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
In vitro labeling of MGC80-3 cells with CC49-QDs Ab probe and primary QDs. (A1/B1/C1/D1) The cell nucleus was stained with DAPI. (A2) MGC80-3 cells labeled with QDs. (B2) MGC80-3 cells labeled with CC49-QDs. (C2) MGC80-3 cells labeled with CC49-QDs after blocked with free CC49. (D2) MGC80-3 cells labeled with fluorescent secondary antibody. A3/B3/C3/D3 were merged with A1 and A2, B1 and B2, C1 and C2, D1 and D2, respectively.
Figure 2
Figure 2
In vitro labeling of GES-1 cells with CC49-QDs Ab probe and primary QDs. (E1/F1/G1/H1) The cell nucleus was stained with DAPI. (E2) GES-1 cells labeled with QDs. (F2) GES-1 cells labeled with CC49-QDs. (G2) GES-1 cells labeled with CC49-QDs after blocked with free CC49. (H2) GES-1 cells labeled with fluorescent secondary antibody. E3/F3/G3/H3 were merged with E1 and E2, F1 and F2, G1 and G2, H1 and H2, respectively.
Figure 3
Figure 3
Powder X-ray diffraction pattern of hydrothermally prepared CdTe QDs (λcm = 600 nm). The line spectra show the cubic CdTe and CdS reflections with their relative intensities.
Figure 4
Figure 4
Physical properties of near-infrared quantum dots. (A) Transmission electron microscope image of QDs. (B) Transmission electron microscope image of CC49-QDs.
Figure 5
Figure 5
Spectrum analysis. (A) The primary CdTe QD spectrum analysis curve. (B) The CC49-QDs spectrum analysis curve.
Figure 6
Figure 6
HPLC elution curves for (A) CC49-QDs and (B) free CC49. The retention times of CC49-QDs and free CC49 were about 6.91 and 9.65 min, respectively.
Figure 7
Figure 7
Immunohistochemical examination of TAG-72 expression. Experimental group: the SP immunohistochemical staining of MGC80-3 (A) and GES-1 (B). Control group (the primary antibody was replaced by PBS): the SP immunohistochemical staining of MGC80-3 (C) and GES-1 (D).

Similar articles

References

    1. Gómez-Martin C, Sánchez A, Irigoyen A, Llorente B, Pérez B, Serrano R, Safont MJ, Falcó E, Lacasta A, Reboredo M, Aparicio J, Dueñas R, Muñoz ML, Regueiro P, Sanchez-Viñes E, López RL. Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. Clin Transl Oncol. 2012;8(9):689–697. doi: 10.1007/s12094-012-0858-3. - DOI - PubMed
    1. Pericleous P, Gazouli M, Lyberopoulou A, Rizos S, Nikiteas N, Efstathopoulos EP. Quantum dots hold promise for early cancer imaging and detection. Int J Cancer. 2012;8:519–528. doi: 10.1002/ijc.27528. - DOI - PubMed
    1. Chen C, Peng J, Sun SR, Peng CW, Li Y, Pang DW. Tapping the potential of quantum dots for personalized oncology: current status and future perspectives. Nanomedicine (Lond) 2012;8(3):411–428. doi: 10.2217/nnm.12.9. - DOI - PubMed
    1. Xue B, Deng DW, Cao J, Liu F, Li X, Akers W, Achilefu S, Gu YQ. Synthesis of NAC capped near infrared-emitting CdTeS alloyed quantum dots and application for in vivo early tumor imaging. Dalton Trans. 2012;8(16):4935–4947. doi: 10.1039/c2dt12436j. - DOI - PubMed
    1. Yang K, Cao YA, Shi C, Li ZG, Zhang FJ, Yang J, Zhao C. Quantum dot-based visual in vivo imaging for oral squamous cell carcinoma in mice. Oral Oncol. 2010;8(12):864–868. doi: 10.1016/j.oraloncology.2010.09.009. - DOI - PubMed

LinkOut - more resources